Sionna Therapeutics
SION | NASDAQ
$3.12
-$0.21 (-6.31%)
At close: Nov 16, 2026, 4:00 PM ET
$3.11
-$0.01 (-0.33%)
After-hours:
Nov 16, 2026, 6:53 PM ET
Sionna Therapeutics Company Profile
Company profile explainedCompany Profile
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan | President, Chief Executive Officer & Director |
| Jennifer Fitzpatrick | Chief Legal Officer & Head of Program Management |
| Vanya Sagar | Chief People Officer |
| Andy Chu | Vice President of Information & Technology |
| Caroline Stark Beer | Chief Business Officer |
| Cecile Le Camus | VP & Head of Medical Affairs |
| Charlotte McKee | Chief Medical Officer & Head of Research and Development |
| Elena H. Ridloff | CFO & Chief Business Officer |
| Erica Iorio | VP of Finance & Controller |
| Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research |
| Juliet Labadorf | Senior Director of Investor Relations & Corporate Development |
| Kenneth A. Lock | Chief Commercial Officer |
| Mara Furlow | Senior Vice President of Global Regulatory Affairs & Quality |
| Mark Munson | Co-founder |
| Mark Trone | Senior VP & Head of CMC |
| Meghan Bagshaw | Vice President & Chief of Staff to CMO |
| Roxanne McGrath | Vice President of Head of Human Resources |
| Sarah J. Spencer | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | SC 13D/A | [Amend] Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
Sionna Therapeutics
| Country | United States |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Michael Cloonan |
Contact Details
21 Hickory Drive Suite 500 Waltham,
Massachusetts 02451 United States
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002036042 |
| CUSIP Number | 829401108 |
| ISIN Number | US8294011080 |
| SIC Code | 2834 |
Recent News
- 3 months ago / benzinga.comSionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
- 3 months ago / barrons.comWhy Sionna Therapeutics Stock Is Crashing 92% to a Record Low
- 3 months ago / seekingalpha.comSionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
- 3 months ago / globenewswire.comSionna Therapeutics Reports Second Quarter 2026 Financial Results
- 5 months ago / seekingalpha.comSionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
- 6 months ago / globenewswire.comSionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
- 6 months ago / globenewswire.comSionna Therapeutics Reports First Quarter 2026 Financial Results
- 7 months ago / globenewswire.comSionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
- 7 months ago / globenewswire.comSionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
- 8 months ago / fool.comSionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
Add to Watchlist
Select watchlists to add or remove SION